6 reports

SIGNIFICANTLY GREATER PAIN RELIEF COMPARED TO THE INJECTABLE STEROID TRIAMCINOLONE ACETONIDE (TA).

  • Heart Attack
  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Sep 16, 2011

This post-hoc analysis provides evidence for the efficacy of CAN-PFS compared with a potent long-acting corticosteroid in providing significant pain relief and reducing incidence of new attacks in GA patients with CKD stage =## with limited treatment options.

  • Heart Attack
  • Hospital
  • Neurology
  • Therapy
  • AstraZeneca PLC
  • May 25, 2011

Novartis announced positive results of two pivotal Phase III trials in patients with severe gouty arthritis, showing that ACZ## (canakinumab) provided superior pain relief and reduced the risk of new attacks by up to ##% compared to an injectable steroid (triamcinolone acetonide, TA) used

  • Cardiovascular Disease
  • Heart Attack
  • Hospital
  • Neurology
  • AstraZeneca PLC
  • May 25, 2011

This post-hoc analysis provides evidence for the efficacy of CAN-PFS compared with a potent long-acting corticosteroid in providing significant pain relief and reducing incidence of new attacks in GA patients with CKD stage =## with limited treatment options.

  • Heart Attack
  • Hospital
  • Neurology
  • Pharmaceutical
  • AstraZeneca PLC
  • THR-100 - DRUG PROFILE
  • Heart Attack
  • Hospital
  • Pharmaceutical
  • Therapy
  • Athersys, Inc.
  • Phase II - Trial Details
  • THR-100 - DRUG PROFILE
  • Chronic Disease
  • Heart Attack
  • United States
  • Product Initiative
  • Athersys, Inc.